UPDATE: Morgan Stanley Reiterates on Express Scripts Following Investor Day

In a report published Monday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on

, and raised the price target from $76.00 to $81.00. In the report, Morgan Stanley noted, “Despite a lackluster investor day and disappointing script outlook, we see a clear roadmap for ESRX to grow EPS 12 to 15% in the next 24 mos. At current valuation and given projected growth & cash profile, we see share upside, without arguing for multiple expansion. Maintain OW, PT to $81 from $76.” Express Scripts closed on Friday at $74.01.